Lab benchwork copy
UroSens is interested in other in-licensing opportunities for cancer biomarkers or technologies where there is a fit with its current platform and products.

UroSens’ assay platform is readily adaptable for the detection of other cancer biomarkers and therefore can provide a rapid route to market based on proven technology.

If your business, university department or other scientific or medical organisation has cancer biomarkers or technologies that might be suitable licensing candidates or if you are interested in collaborating with UroSens in the development of a cancer diagnostic, please get in touch.